天坛生物(600161.SH):子公司仅为新型冠状病毒特免血浆疗法提供设备及技术支持
天坛生物(600161.SH)关注到相关媒体报道,经查,报道所述新型冠状病毒特免血浆治疗工作为公司控股股东中国生物技术股份与相关机构合作开展,报道提及的新型冠状病毒特免血浆疗法属於医疗技术,目前不纳入药品管理,不属於公司主营业务范畴。
公司表示,下属子公司仅为血浆疗法提供设备及技术等支持,相关工作不会对公司的产品结构和主营业务产生影响。报道提及的新型冠状病毒特免球蛋白目前正处於研发初期,後续研发情况存在不确定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.